Trial Profile
A Phase 1 Open-Label, Parallel-Group, Single-Dose Study to Evaluate the Pharmacokinetics of GS-9857 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 23 Mar 2020
Price :
$35
*
At a glance
- Drugs Voxilaprevir (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Gilead Sciences
- 17 Apr 2016 Preliminary results presented at The International Liver Congress™ 2016
- 15 Mar 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 11 Jan 2016 Planned End Date changed from 1 Dec 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov.